Intellia Therapeutics, Inc. (NTLA) stock analysis

NTLA · Intellia Therapeutics, Inc.

Latest recorded price: USD 9.86

Sector and industry: Healthcare · Biotechnology

Fiscal 2025 figures: revenue growth 9.1%, free cash flow margin -585.0%, ROIC -128.5%. The model flags 1 risk signal for this company (1 high severity).

Similar companies in Healthcare